Thairm Bio, Kineticos and Scottish National Investment Bank led a $34m round in EnteroBiotix.

Thairm Bio, a venture capital firm, Kineticos, a growth and venture investor, and Scottish National Investment Bank, led a $34m round in EnteroBiotix, a clinical-stage biopharmaceutical company developing microbial therapeutics, with participation from Scottish Enterprise. “This significant new investment helps enable our vision of transforming the standard of care for patients suffering from serious conditions linked to the gut microbiome. It will help accelerate the development of our innovative product pipeline and propels us towards our goal of bringing these innovative treatments to market. We look forward to working closely with our new partners at the Bank and with our existing investors to bring this vision to fruition, for the benefit of patients across the globe,” Dr James McIlroy, EnteroBiotix CEO.